John C. Doyle
Director/Board Member at Altrubio, Inc.
Profile
John C.
Doyle is currently a Director at Altrubio, Inc. and a Member at The Aspen Institute, Inc. He was previously the Chief Executive Officer & Director at Castlight Health, Inc. from 2017 to 2019, and an Independent Director at Achaogen, Inc. from 2012 to 2019.
Prior to that, he was the Vice President-Finance & Corporate Planning at Genentech, Inc. from 2007 to 2009, the Chief Financial Officer at Renovis, Inc. from 2002 to 2009, and a Principal at PricewaterhouseCoopers International Ltd.
He also worked as a Controller at Tularik, Inc. Mr. Doyle received an undergraduate degree from California Polytechnic State University (San Luis Obispo) and an MBA degree from Haas School of Business.
John C. Doyle active positions
Companies | Position | Start |
---|---|---|
The Aspen Institute, Inc.
The Aspen Institute, Inc. Miscellaneous Commercial ServicesCommercial Services The Aspen Institute operates an institution that fosters leadership skills and open-minded dialogue. It conducts seminars, policy programs, conferences and leadership development initiatives, the Institute and its international partners seek to promote nonpartisan inquiry. The company was founded in 1949 and is headquartered in Washington, DC. | Corporate Officer/Principal | - |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | Director/Board Member | - |
Former positions of John C. Doyle
Companies | Position | End |
---|---|---|
CASTLIGHT HEALTH, INC. | Chief Executive Officer | 2019-07-25 |
ACHAOGEN | Director of Finance/CFO | 2012-10-31 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Director of Finance/CFO | 2009-05-31 |
PricewaterhouseCoopers International Ltd.
PricewaterhouseCoopers International Ltd. Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers International Ltd. operates as an international association of accounting and consultancy firm. The company was founded on June 24, 1998 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Comptroller/Controller/Auditor | - |
Training of John C. Doyle
California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
Haas School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 8 |
---|---|
Renovis, Inc.
Renovis, Inc. Pharmaceuticals: MajorHealth Technology Renovis, Inc. develops pharmaceutical products. The company discovers, develops, and commercializes novel therapeutics for neurological and inflammatory diseases. It is headquartered in San Francisco, CA | Health Technology |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
PricewaterhouseCoopers International Ltd.
PricewaterhouseCoopers International Ltd. Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers International Ltd. operates as an international association of accounting and consultancy firm. The company was founded on June 24, 1998 and is headquartered in London, the United Kingdom. | Commercial Services |
Castlight Health, Inc.
Castlight Health, Inc. Packaged SoftwareTechnology Services Castlight Health, Inc. engages in the provision of healthcare information technology solutions. It offers health benefits platforms which enables benefit leaders to communicate and measure their programs. The company was founded by Todd Y. Park, Bryan E. Roberts and Giovanni M. Colella in January 2008 and is headquartered in San Francisco, CA. | Technology Services |
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
The Aspen Institute, Inc.
The Aspen Institute, Inc. Miscellaneous Commercial ServicesCommercial Services The Aspen Institute operates an institution that fosters leadership skills and open-minded dialogue. It conducts seminars, policy programs, conferences and leadership development initiatives, the Institute and its international partners seek to promote nonpartisan inquiry. The company was founded in 1949 and is headquartered in Washington, DC. | Commercial Services |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | Retail Trade |
- Stock Market
- Insiders
- John C. Doyle